Published On: Sep 16, 2024
Last Updated On: Sep 16, 2024
Today the eczema community is one step closer to having a new treatment option. The U.S. Food and Drug Administration (FDA) has approved Ebglyss (lebrikizumab-lbkz) from manufacturer Eli Lilly and Company for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis that is not well controlled despite treatment with topical prescription therapies.
Ebglyss is a targeted IL-13 inhibitor that works by targeting eczema inflammation throughout the body that can lead to dry, itchy and irritated skin.
It’s important to talk to your doctor about how atopic dermatitis affects your skin and other aspects of your life. Together, you and your healthcare provider can determine if Ebglyss is an appropriate treatment option.
Learn more about Ebglyss and other new prescription treatment therapies on our website.
The U.S. Food and Drug Administration (FDA) has approved Zoryve cream (roflumilast 0.15%) from manufacturer Arcutis Biotherapeutics, for the treatment of atopic dermatitis in adults and children ages 6 and older.
Cibinqo (abrocitinib) has been approved by the U.S. Food and Drug Administration (FDA). Cibinqo, from manufacturer Pfizer, will be available by prescription only.
Today the eczema community is one step closer to having a new treatment option. Adbry™ (tralokinumab-ldrm), a biologic medication for adults (18+) with moderate to severe atopic dermatitis (AD) for whom topical prescription treatments have not adequately worked or are not advised, has been approved by the U.S. Food and Drug Administration (FDA).
Evidence-based articles, expert-sourced lifestyle tips and stories from your community.